AbbVie faces questions about Skyrizi competition from J&J
Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the discussion focused on whether megablockbuster Skyrizi is ...
April 29, 2026 02:52 PM EDT Pharma As AbbVie posts more strong Skyrizi sales, Wall Street frets over J&J pill Max Gelman Senior Editor Threats to AbbVie’s immunology dominance took center stage on the company’s first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that